HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
NCATS Advisory Council

Council Subcommittee on Pharma/Biotech/VC Interactions

The NCATS Advisory Council Subcommittee on Pharma, Biotech and Venture Capital Interactions was established at the September 2013 Advisory Council meeting. The mission of the subcommittee was to provide recommendations to NCATS on ways it could maximize awareness and effectiveness of existing programs with commercial partners such as pharma and biotech. The subcommittee also explored ideas and models that could further NCATS' visibility and effectiveness in developing strategic public-private partnerships that stimulate and facilitate innovation in translational science.

This currently inactive subcommittee included members who have extensive expertise in subject areas relevant to collaborations and interactions with large pharma, biotech, small business and venture capital groups. Their insights and perspectives were critical to NCATS in developing an innovative and robust partnership and collaboration ecosystem with various stakeholders in the translational research space.

Subcommittee Members

Co-Chairs

Freda C. Lewis-Hall, M.D.
Chief Medical Officer
Pfizer
New York, New York

Ankit A. Mahadevia, M.D., M.B.A.
Venture Partner
Atlas Venture
Cambridge, Massachusetts

Members

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
Bethesda, Maryland

Louis J. DeGennaro, Ph.D.
President and CEO
Leukemia & Lymphoma Society
White Plains, New York

NCATS Liaisons

Carson R. Loomis, Ph.D.
Senior Advisor to the Director
Office of the Director
National Center for Advancing Translational Sciences

Gurusingham S. Sittampalam, Ph.D.
Senior Advisor to the Director
Office of the Director
National Center for Advancing Translational Sciences

Last updated: 08-14-2015
▲ Back to top